Updates are available Correction dated 2023-10-02
Click to view Correction: https://doi.org/10.1038/s41408-023-00926-3
-
Authors
Tam, Constantine S. http://orcid.org/0000-0002-9759-5017
Muñoz, Javier L. http://orcid.org/0000-0002-9060-8911
Seymour, John F. http://orcid.org/0000-0003-2188-6835
Opat, Stephen http://orcid.org/0000-0002-0308-6458
-
Funding
Funding for this research was provided by:
Medical writing and editorial assistance were provided, under the direction of the authors, by Alberto Moldón, PhD, of Bio Connections, LLC (Chicago, IL), and supported by BeiGene USA, Inc.
- License Information
-
More Information
Article History
Received: 13 June 2023
Revised: 1 August 2023
Accepted: 14 August 2023
First Online: 11 September 2023
Change Date: 2 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-023-00926-3
Competing interests
: JM reports consulting fees from ADC Therapeutics, Alexion, Bayer, BeiGene, BMS, Debiopharm, Epizyme, Fosun Kite, Genmab, Gilead/Kite Pharma, Innovent, Janssen, Juno/Celgene, Karyopharm, Kyowa, MorphoSys/Incyte, Novartis, Pfizer, Pharmacyclics/AbbVie, Seagen, and Servier; research funding from Bayer, Celgene, Genentech, Gilead/Kite Pharma, Incyte, Janssen, Merck, Millennium, Pharmacyclics, Portola, and Seagen; honoraria from Curio, Kyowa, OncView, Physicians’ Education Resource, Seagen, and Targeted Oncology; and speakers bureau for Acrotech/Aurobindo, AstraZeneca, Bayer, BeiGene, Celgene/BMS, Genentech/Roche, Gilead/Kite Pharma, Pharmacyclics/Janssen, Kyowa, Seagen, and Verastem. JFS reports research funding from AbbVie, BMS, and Roche; and advisory board/honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Genentech, Genor Bio, Gilead, Janssen, Roche, Sunesis, and TG Therapeutics. CST received research support from Janssen and AbbVie; received honoraria from BeiGene, AbbVie, and Janssen; and received other remuneration from BeiGene. SO reports funding from BeiGene paid to Monash University, with regards to the submitted work; receiving honoraria and participating on an advisory board for BeiGene, outside the submitted work.
